Delving into the Latest Updates on Furen Medicines Group Co., Ltd. with Synapse

Overview

Tags

Endocrinology and Metabolic Disease

Digestive System Disorders

Urogenital Diseases

Small molecule drug

Interleukins

Interferons

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	3
Neoplasms	2
Infectious Diseases	2
Immune System Diseases	2
Hemic and Lymphatic Diseases	2
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	4
Interferons	1
Interleukins	1

Top 5 Target	Count

IFNAR(Interferon alpha/beta receptor)	1
COX-1(Cyclooxygenase-1)	1
IL-2R(Interleukin-2 receptor)	1
DNA polymerase x RT	1

主要目的：考察辅仁药业集团有限公司生产的头孢氨苄胶囊（受试制剂，125 mg/粒）与Takeda Pharmaceutical Co., Ltd.生产的头孢氨苄胶囊（参比制剂，Sencephalin®，125 mg/粒）的药代动力学参数和相对生物利用度，进行空腹和餐后条件下单次服药（250 mg）的人体生物等效性试验，进行上市后药品一致性评价。次要目的：观察受试制剂与参比制剂在健康受试者中给药后的安全性。

[Translation]

Primary objective: To investigate the pharmacokinetic parameters and relative bioavailability of Cephalexin Capsules (test preparation, 125 mg/capsule) produced by Furen Pharmaceutical Group Co., Ltd. and Cephalexin Capsules (reference preparation, Sencephalin®, 125 mg/capsule) produced by Takeda Pharmaceutical Co., Ltd., to conduct a single dose (250 mg) bioequivalence study in humans under fasting and postprandial conditions, and to conduct a post-marketing drug consistency evaluation. Secondary objective: To observe the safety of the test preparation and the reference preparation after administration in healthy subjects.

Start Date28 Sep 2018

Sponsor / Collaborator

Furen Medicines Group Co., Ltd.

CTR20180817 / Completed

评价健康志愿者空腹和餐后单次口服多潘立酮片单中心、开放、随机、两周期、自身交叉生物等效性

[Translation] Evaluation of the single-center, open-label, randomized, two-period, self-crossover bioequivalence of fasting and fed single oral doses of domperidone tablets in healthy volunteers

主要目的：以中国健康受试者为对象，考察辅仁药业集团有限公司生产的多潘立酮片（受试制剂，10 mg/片）与Janssen-Cilag, France生产的Motilium（参比制剂，10 mg/片）空腹和餐后单次给药的人体生物等效性。次要目的：观察给药后的安全性。

[Translation]

Primary objective: To investigate the bioequivalence of domperidone tablets (test preparation, 10 mg/tablet) produced by Furen Pharmaceutical Group Co., Ltd. and Motilium (reference preparation, 10 mg/tablet) produced by Janssen-Cilag, France, after single administration on an empty stomach or after a meal in healthy Chinese subjects. Secondary objective: To observe the safety after administration.

Start Date18 May 2018

Sponsor / Collaborator

Furen Medicines Group Co., Ltd.

CTR20140521 / Active, not recruitingPhase 1

阿德福韦酯分散片人体生物等效性试验

[Translation] Bioequivalence study of adefovir dipivoxil dispersible tablets in human subjects

观察健康受试者服用阿德福韦酯分散片血药浓度经时过程，以葛兰素史克的贺维力为参比制剂，计算其相应的药代动力学参数和相对生物利用度，同时对受试制剂和参比制剂的生物等效性进行评价。

[Translation]

The time course of blood drug concentration of adefovir dipivoxil dispersible tablets in healthy subjects was observed. GlaxoSmithKline's Hevily was used as the reference preparation. The corresponding pharmacokinetic parameters and relative bioavailability were calculated, and the bioequivalence of the test preparation and the reference preparation was evaluated.

Start Date17 Sep 2013

Sponsor / Collaborator

Furen Medicines Group Co., Ltd.

100 Clinical Results associated with Furen Medicines Group Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Furen Medicines Group Co., Ltd.

Login to view more data

5

Literatures (Medical) associated with Furen Medicines Group Co., Ltd.

Zhonghua Shiyan He Linchuang Bingduxue Zazhi

Interferon and its clinical application

Author: Zhang, Liping

A review.A review with 9 references on species and formulation of interferon for clin. application, theor. basis for clin. application of interferon-α, its clin. application to treatment of neoplasm and its clin. application to treatment of viral diseases.

Zhonghua Shiyan He Linchuang Bingduxue Zazhi

Curative effect of interferon for treating neoplasms

Author: Han, Yanhong

A review.A review with 14 references on curative effect of interferon for treating neoplasms, such as hairy cell leukemia, chronic myeloid leukemia, melanoma, renal cell carcinoma, pulmonary carcinoma, gastrointestinal carcinoma and so on.

Zhonghua Shiyan He Linchuang Bingduxue Zazhi

Side effect of interferon-α2b in clinical therapy

Author: Wei, Xuejun ; Hou, Yunde

This review with 8 references is given on the side effects of interferon-β2b in treatment of chronic hepatitis B, chronic hepatitis C, hairy cell leukemia, malignant melanoma, follicular lymphoma, condylomata acuminata and AIDS related Kaposi sarcoma, and also the side effects of long- acting interferon-α2b and combination therapy.

100 Deals associated with Furen Medicines Group Co., Ltd.

Login to view more data

100 Translational Medicine associated with Furen Medicines Group Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

4

2

Approved

Other

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recombinant human interleukin-2(Beijing Yuance Pharmaceutical Co Ltd) ( IL-2R )	Neoplasms More	Approved
Recombinant human interferon α2b(Beijing Yuance Pharmaceutical Co Ltd) ( IFNAR )	Bladder Cancer More	Approved
Triflusal ( COX-1 )	-	Phase 1
Sodium Feredetate	-	Phase 1
Adefovir Dipivoxil ( DNA polymerase x RT )	-	Phase 1